KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Free Cash Flow (2016 - 2025)

Novavax has reported Free Cash Flow over the past 16 years, most recently at -$39.2 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$39.2 million for Q4 2025, up 78.77% from a year ago — trailing twelve months through Dec 2025 was -$244.6 million (down 143.82% YoY), and the annual figure for FY2025 was -$244.6 million, down 143.82%.
  • Free Cash Flow for Q4 2025 was -$39.2 million at Novavax, down from $109.1 million in the prior quarter.
  • Over the last five years, Free Cash Flow for NVAX hit a ceiling of $649.3 million in Q1 2021 and a floor of -$352.7 million in Q4 2021.
  • Median Free Cash Flow over the past 5 years was -$118.8 million (2022), compared with a mean of -$58.6 million.
  • Peak annual rise in Free Cash Flow hit 2894.87% in 2021, while the deepest fall reached 761.24% in 2021.
  • Novavax's Free Cash Flow stood at -$352.7 million in 2021, then soared by 68.88% to -$109.8 million in 2022, then plummeted by 61.28% to -$177.0 million in 2023, then fell by 4.29% to -$184.6 million in 2024, then soared by 78.77% to -$39.2 million in 2025.
  • The last three reported values for Free Cash Flow were -$39.2 million (Q4 2025), $109.1 million (Q3 2025), and -$127.7 million (Q2 2025) per Business Quant data.